Board member
(PharmD, LL.M, MBA)
Pierre is currently the CEO of MRGN Advisors, Executive VP of CanSino Biologics, Resgional partners at Merieux Equity Partners; Board Chairman and Non-Executive Director at Univercells.
He has a strong background in the pharmaceutical and biotechnology industries, with expertise in business development, strategic planning, and regulatory affairs.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens